TNF and Hypoglycemia: Although some studies documented that FMD ameliorated T2D by inhibiting the inflammatory cytokines such as interleukin (IL)-1β, IL-4, IL-6, and tumor necrosis factor (TNF)-α [8, 9], its capacity of glycemic control may be unstable, and sometimes may even cause hypoglycemia, long-term treatment must be performed to achieve the expected therapeutic effects [6, 10].